Literature DB >> 11221880

The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.

D A Levine1, J Boyd.   

Abstract

Our objectives were to test whether polymorphic variation in the (CAG)n repeat of the androgen receptor (AR) gene affects penetrance of germ-line BRCA mutations for ovarian cancer or age of diagnosis for ovarian cancer. Using a case-series study design, 179 consecutive Ashkenazi Jewish ovarian cancer patients were genotyped for AR repeat length and BRCA mutation status. There was no association between AR repeat length and presence of a BRCA mutation. However, ovarian cancer patients from both groups (with or without BRCA mutation) who carried a short AR allele were diagnosed an average of 7.2 (95% confidence interval, 2.3-12.1) years earlier than patients who did not carry a short allele (P = 0.004). These data suggest that AR allele length affects age of diagnosis of ovarian cancer, irrespective of BRCA mutation status.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221880

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

2.  Androgen receptor trinucleotide polymorphism in leiomyoma.

Authors:  Yao-Yuan Hsieh; Chi-Chen Chang; Fuu-Jen Tsai; Cheng-Chieh Lin; Lian-Shun Yeh; Ching-Tien Peng
Journal:  J Assist Reprod Genet       Date:  2004-12       Impact factor: 3.412

Review 3.  Hereditary ovarian cancer in Ashkenazi Jews.

Authors:  Luis Robles-Díaz; Deborah J Goldfrank; Noah D Kauff; Mark Robson; Kenneth Offit
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.

Authors:  Sharon Simchoni; Eitan Friedman; Bella Kaufman; Ruth Gershoni-Baruch; Avi Orr-Urtreger; Inbal Kedar-Barnes; Ronit Shiri-Sverdlov; Efrat Dagan; Sigal Tsabari; Mordechai Shohat; Raphael Catane; Mary-Claire King; Amnon Lahad; Ephrat Levy-Lahad
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

5.  PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.

Authors:  Mary T Galgano; Mark Conaway; Adam M Spencer; Bryce M Paschal; Henry F Frierson
Journal:  Hum Pathol       Date:  2009-05-07       Impact factor: 3.466

6.  Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer.

Authors:  Martin Ligr; Ruzeen Rohintan Patwa; Garrett Daniels; Lorraine Pan; Xinyu Wu; Yirong Li; Liantian Tian; Zhenxing Wang; Ruliang Xu; Jingjing Wu; Fan Chen; Jinsong Liu; Jian-Jun Wei; Peng Lee
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

7.  Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles.

Authors:  Ashley J R Carter; Andrew Q Nguyen
Journal:  BMC Med Genet       Date:  2011-12-12       Impact factor: 2.103

Review 8.  Antagonistic Pleiotropy in Human Disease.

Authors:  Sean G Byars; Konstantinos Voskarides
Journal:  J Mol Evol       Date:  2019-12-21       Impact factor: 3.973

Review 9.  Ovarian surface epithelium: family history and early events in ovarian cancer.

Authors:  Alice S T Wong; Nelly Auersperg
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

10.  The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer.

Authors:  Xiangrui Meng; Peng Lu; Zhi Chu; Qingxia Fan
Journal:  Oncotarget       Date:  2016-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.